Project Overview +

Approximately 40% of obese patients with breast cancer undergoing chemotherapy receive reduced doses of chemotherapy despite nearly two decades of evidence supporting full weight-based dosing. This project aims to share evidence that supports full dosing for obese breast cancer patients with physicians.

Related Media +

Related Media:

Aims +

Aim 1: Investigate knowledge, attitudes, and beliefs of oncologists associated with reduced versus full weight dosing in the treatment of solid tumors in the curative setting.

Aim 2: Provide tailored feedback to oncologists about optimal dosing of adjuvant chemotherapy for breast cancer.

Aim 3: Assess the effect of this intervention on improvement in full weight dosing of adjuvant chemotherapy for breast cancer, and effects on changes in use of full weight dosing for other solid tumors. The data from this developmental project will be used to generate pilot data for an R01 application.

Participants +

Medical oncologists who are members of the Michigan Cancer Consortium and who treat breast cancer patients

Intervention +

Participants complete a brief baseline survey to assess dosing practices. Participants then receive tailored feedback highlighting evidence to support full-weight dosing. Reference materials are provided to address participant concerns about full-weight dosing.

Findings +

Initial analysis: The investigative team examined the knowledge, attitudes, and beliefs of oncologists with respect to chemotherapy dose selection in obese patients receiving adjuvant (curative) chemotherapy. Specifically, participants were asked if they use full weight-based doses of chemotherapy or if they limit chemotherapy doses in their obese patients. The program provided oncologists with tailored feedback about evidence-based chemotherapy dose selection. Oncologists who treated breast cancer were resurveyed 3 months later to see if their dosing practices had changed in response to the feedback they received from the website. A total of 71 oncologists consented to participate in the study, and 69 completed the time one (baseline survey). Of these, 41 oncologists said they saw breast cancer patients, and 10 of those completed the follow-up survey. Other analyses are ongoing as we anticipate that more respondents will complete the time 2 survey.

ChemoDosing

01/01/2010 - 12/31/2010

Sponsor(s)

National Cancer Institute

Principal Investigators:

Tunghi May Pini, MD, MPH
Jennifer J. Griggs, MD, MPH

Co-Investigator(s):

Sarah T. Hawley, PhD, MPH